Case 1: Standard-risk, Younger Double Refractory Patient

Patients with multiple myeloma that is refractory to both bortezomib and lenalidomide have an especially poor prognosis. This double-refractory indication is emerging as a significant clinical challen... Author: imedex Added: 06/05/2014
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts